Healthy Aging Health Center
Running Slows the Effects of Aging
Aug. 11, 2008 -- Regular running slows the effects of aging, according to a new study from the Stanford University School of Medicine that tracked 500 older runners for more than 20 years.
Older runners have fewer disabilities, remain more active as they get into their 70s and 80s, and are half as likely as non-runners to die early deaths, the study shows.
Exercise Videos
Related Slideshows
"If you had to pick one thing to make people healthier as they age, it would be aerobic exercise," James Fries, MD, an emeritus professor of medicine at the medical school and the study's senior author, says in a news release.
Researchers tracked 538 runners over age 50, comparing them to a similar group of 423 non-runners. The runners were part of a nationwide running club.
The participants, now in their 70s and 80s, answered yearly questionnaires about their ability to perform everyday activities such as walking, dressing, grooming, getting out of a chair, and gripping objects. The researchers used national death records to learn which participants died and why. Nineteen years into the study, 34% of the non-runners had died, compared with only 15% of the runners.
At the beginning of the study, the runners ran an average of about four hours a week. After 21 years, their running time declined to an average of 76 minutes per week.
Everyone in the study became more disabled after 21 years, but for runners the onset of disability started later. Perhaps not surprisingly, running was linked to lower rates of cardiovascular deaths from causes such as stroke and heart attack. However, it also was associated with fewer early deaths from cancer, neurological disease, infections, and other causes, according to the findings.
The study appears in the Aug. 11 edition of Archives of Internal Medicine.
del.icio.us
VIVELLE-DOT (estradiol transdermal system) IS AVAILABLE BY PRESCRIPTION ONLY.
INDICATION
Vivelle-Dot is used after menopause to: reduce moderate to severe hot flashes; treat moderate to severe dryness, itching and burning in or around the vagina; help reduce your chances of getting osteoporosis (thin weak bones); and treat certain conditions in which a young woman's ovaries do not produce enough estrogens naturally. Vivelle-Dot 0.025 mg/day is only used to prevent osteoporosis from menopause. If you use Vivelle-Dot only to treat your dryness, itching, and burning in and around your vagina or if you use Vivelle-Dot only to prevent osteoporosis from menopause, talk with your healthcare professional about whether a different treatment or medicine without estrogens might be better for you.
IMPORTANT SAFETY INFORMATION
Estrogens increase the chances of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are taking estrogens. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Do not use estrogens with or without progestins to prevent heart disease, heart attacks, or strokes. Using estrogens with or without progestins may increase your chances of getting heart attacks, strokes, breast cancer, and blood clots. Using estrogens with progestins may increase your risk of dementia (decline in memory and thinking skills).
Vivelle-Dot should not be used if you have unusual vaginal bleeding; currently have or have had certain cancers, including cancer of the breast or uterus; had a stroke or heart attack in the recent past (for example, in the past year); currently have or have had blood clots; currently have or have had liver problems; or think you may be, or know that you are, pregnant.
The most common side effects that may occur with Vivelle-Dot are headache, breast tenderness, and back pain.
You and your healthcare professional should talk regularly about whether you still need treatment with Vivelle-Dot.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Full Prescribing Information for Vivelle-Dot.
